Latest News

Saturday, 25 June 2016

New study highlights progesterone benefit for breast cancer

An international study including researchers from the University of Adelaide shows the potential benefit of adding progesterone to standard breast cancer treatments.

Published today in Science Advances, the study reports that treatments aimed at the progesterone receptor, a protein activated by progesterone, could prolong life in women with estrogen-driven breast cancer beyond current standard treatments which target the estrogen receptor alone. These standard treatments are tamoxifen or aromatase inhibitors.

“About 75-80% of breast cancers are driven by the female hormone, estrogen,” says Professor Wayne Tilley, Director of the University of Adelaide’s Dame Roma Mitchell Cancer Research Laboratories. “One of the first clues pathologists look for in tissue from a newly diagnosed breast cancer patient is the estrogen receptor, a protein in tumour cells that transmits the growth-promoting signals of estrogen hormones in the body. They also look for the presence of progesterone receptors, primarily to confirm that the estrogen receptor is active.”

The role of estrogen in driving tumour growth in breast cancers is well established, but the role of progesterone is the topic of much controversy.

The study, led by Professor Geoffrey Greene at the University of Chicago in collaboration with Professor Tilley at the University of Adelaide, employed a special technique for modelling breast cancer developed by the Adelaide group. This model allows researchers to test potential new treatments directly on breast cancer tissue donated by patients.

Building on earlier work by the University of Adelaide and the Cancer Research UK Cambridge Institute, the new study independently confirms and provides new insight into how progesterone receptors reprogram the actions of estrogen receptor, with an overall “braking effect” on tumour growth.

“We have known for some time that the progesterone receptor plays an important role in breast cancer, but gaps in our knowledge of the function of this receptor in breast tumours have limited the potential to develop new treatments,” says Professor Tilley. “This independent study provides important preclinical validation for initiation of clinical trials testing progesterone in combination with current standard-of-care therapy.

“Use of progesterone for treatment of breast cancer has raised considerable controversy because of past studies showing some negative effects of synthetic versions of progesterone used in hormonal therapy for postmenopausal women. In our studies, we are using natural progesterone, or forms of this hormone that are biologically identical to the natural hormone, and testing it on breast cancer tissue taken from women with cancer.”

The researchers also identified a new progesterone receptor targeting drug that not only opposed the action of estrogen in breast cancers to halt tumour growth, but actually caused the tumours to regress. This new drug is now poised to enter the clinical trial phase.

“Our study helps resolve the controversy over whether progesterone is good or bad for women with breast cancer,” says Dr Theresa Hickey, Senior Research Fellow in the Dame Roma Mitchell Cancer Research Laboratories. “The next question is how best to exploit it for the benefit of women with this disease.”

Professor Tilley says that a clinical trial will start in the UK this year. “We have also initiated proposals for a trial in Australia to thoroughly test this potentially life-extending treatment for breast cancer patients,” he says. [Full Story]

RSS News Feed

Latest Headlines

Friday, 24 June 2016

Adelaide sports engineers aim to give Tour cyclists the edge

University of Adelaide sports engineers have helped to develop what is believed to be the world's fastest road cycling helmet. [Full Story]

Friday, 24 June 2016

Long lens of the law captures Images of Justice

All photographers are invited to submit their "images of justice" to this year's photographic competition run by the University of Adelaide's Law School. [Full Story]

Friday, 24 June 2016

A-grade report card on superbugs in Australian animals

The first nationwide survey of antibiotic resistance in disease-causing bacteria in Australian pets and livestock has found low rates of resistance to critically important drugs. [Full Story]

Thursday, 23 June 2016

Increasing militarisation of space prompts legal response

New research aims to better understand how international law will regulate the increasing military uses of space. [Full Story]

Upcoming Events

Reminiscences of the Great War: A Flanders Fields Poppy Trail 2016 Exhibition

Friday, 17 June 2016 - Friday, 26 August 2016
Barr Smith Library, Rare Books & Special Collections, Level 1

Free Guided Walk at the Waite Arboretum

Sunday, 3 July 2016, 11:00 am to 12:30 pm
Meet at Urrbrae House, Walter Young Drive, Urrbrae House, Urrbrae

South Australia's Lost Children

Wednesday, 6 July 2016, 5:00 pm to 7:30 pm
Rumours cafe, 6th floor, Union House, North Tce campus

The Millennial Doctor

Wednesday, 6 July 2016, 5:30 pm to 6:30 pm
Napier Theatre Lecture 102, Level 1, Napier building, North terrace campus

Urrbrae House Free Guided Tour

Tuesday, 12 July 2016, 11:00 am to 12:30 pm
Urrbrae House, Walter Young Drive (off Fullarton Rd) Urrbrae

Find an Expert

Events Calendar

< June 2016 >
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30

News Publications

The Adelaidean provides news about the teaching, research and other activities of the University.

The University's bi-annual alumni magazine.

Staff News
The University's weekly newsletter keeping staff informed about what's on.

The Media Unit

For help with finding an expert for your story or the latest news from the University of Adelaide, please contact one of the Media Officers below:

Lachlan Parker
Deputy Director
Media & Corporate Relations
work: +61 8 8313 3196
mobile: +61 417 810 890

David Ellis
Media and Communications Officer
work: +61 8 8313 5414
mobile +61 421 612 762

Robyn Mills
Media and Communications Officer
work: +61 8 8313 6341
mobile +61 410 689 084